HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$16.43
Price-0.12%
-$0.02
1Y
Price
Market Cap
$2.866b
Mid
Price/Earnings 3y Avg5y Avg
6.2x
Premium
Premium
Financials Overview
Key metrics over the past few years-29.1%
EBITDA Margin-22.2%
Net Profit Margin-11.3%
Free Cash Flow MarginRevenue
$630.201m
+196.3%
1y CAGR+90.8%
3y CAGR+70.9%
5y CAGREarnings
$37.729m
+136.5%
1y CAGR+13.1%
3y CAGR+1.1%
5y CAGREPS
$0.22
+231.3%
1y CAGR+54.1%
3y CAGR+33.7%
5y CAGRBook Value
$771.853m
$1.274b
Assets$502.343m
Liabilities$89.820m
DebtDebt to Assets
7.0%
2.3x
Debt to EBITDAFree Cash Flow
-$17.436m
+193.0%
1y CAGR-5.3%
3y CAGR-1.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company